Oncology Clinical Trials
Theratechnologies is currently conducting a Phase 1 clinical trial for its investigational PDC.
The clinical trial protocol can be found at: https://clinicaltrials.gov/ct2/show/NCT04706962?recrs=ab&cond=th1902&draw=2&rank=1
The goals of the Phase 1 clinical are to establish the maximum-tolerated dose (MTD) and the safety, pharmacokinetics, and preliminary anti-tumor activity of TH1902 administered once every three weeks in patients with advanced solid tumors refractory to available anti-cancer therapies.
Once the MTD is determined, part 2 of the Phase 1 will be initiated, where additional patients with SORT1+ tumors will be enrolled into a basket design to evaluate the potential anti-tumor activity and safety of TH1902 in patients with multiple tumor types known to express sortilin.
People interested to participate in this clinical trial should ask their treating physician to contact one of the following clinics to determine if they are still recruiting patients and if they are eligible candidates for the Phase 1 clinical trial. The detailed Phase 1 study protocol is available at www.clinicaltrials.gov under the identifier number: NCT04706962.
Dr. Funda Meric-Berstam, Principal investigator
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Dr. Satish Shah
Gettysburg Cancer Center
Gettysburg, Pennsylvania, United States, 17325